Novo Nordisk Pharma Co., Ltd.
Basic information
- Head office
- Chief executive
- Keisuke Kotani
- Capital
- 2,104,050,000 JPY (21 100 millionJPY)
- Employees (non-consolidated)
- Employees (consolidated)
- Start date
- 1980-06-20
- End date
Websites
Business
Related companies
—
Network
History
The brothers, former employees of Nordisk, Harald Pedersen and Torvald Pedersen, founded the Novo Therapeutics Institute. Novo and Nordisk engaged in fierce competition until they merged in 1989 to form Novo Nordisk A/S.![]()
Former Novo Nordisk employees Harald Pedersen and Torvald Pedersen, brothers, founded Novo Therapeutics Research Institute.![]()
In 1946, NPH (Neutral Protamine Hagedorn) insulin was developed and quickly became the majority of long‑acting insulin preparations used worldwide. The introduction of NPH reduced the number of injections needed for people with diabetes. The product was named after Hans Christian Hagedorn, who discovered the long‑acting effect of protamine on insulin.![]()
Novo Pharmaceutical releases pen-type insulin injector and dedicated insulin cartridge formulation, along with dedicated injection needles.![]()
In 2001, in response to a patent dispute that arose in South Africa, Novo Nordisk developed a long‑term strategy to support access to treatment in the world’s poorest countries. The strategy included the establishment of the World Diabetes Foundation (2002) and the Novo Nordisk Hemophilia Foundation (2005), as well as differentiated pricing policies for insulin targeting developing countries.![]()
In response to a patent dispute arising in South Africa, Novo Nordisk devised a long-term strategy to support access to treatment in the world's poorest countries.![]()
In 2005, more than ten years after the introduction of the "Novo Nordisk Way of Management," which set a vision and policy applicable to all employees worldwide, the company introduced the "Novo Nordisk Way," emphasizing its history and values.![]()
More than ten years after introducing the "Novo Nordisk Way of Management"—a vision and policy applicable to all employees worldwide—Novo Nordisk introduced the "Novo Nordisk Way" to emphasize the company's history and values.![]()
In 2014, as a public‑private partnership addressing the impact of urban life on the rise of chronic diseases, the company launched the "Cities Changing Diabetes" program, focusing on prevention.![]()
As a public-private partnership addressing the impact of urban living on the rise of chronic diseases, we launched the "Cities Changing Diabetes" program, focusing on prevention of diabetes spread in cities.![]()
Novo Nordisk celebrates its 100th anniversary, a milestone and opportunity, renewing its commitment to drive transformation toward a healthier world for the current and next generations.![]()
In 2021, the company expanded its partnership with UNICEF, working to create healthier environments for children and address childhood overweight and obesity.![]()
News
There is no news.